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A survey of nebulisation practice in France was conducted under the aegis of the French
respiratory society in 2004.
Methods: Analysis of a questionnaire was obtained from 3674 physicians.
Results: A total of 2439 physicians were general practitioners (GPs), 698 were chest
physicians, and 537 paediatricians. The main reasons to use nebulisation are (1) for chest
physicians efﬁcacy in treating various pathologies with long-term administration (1wk to
X1 month) of approved drugs, and (2) for GP’s local action properties. While chest
physicians learned about nebulisation during their university training and do not ask for
additional information, GPs learned by practical experience or from colleagues and ask for
further information.
Conclusion: This study will help to develop targeted educational programmes on
nebulisation practice.
& 2007 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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M. de Monte et al.2562Introduction
French guidelines for nebulisation were published in
1997 under the aegis of the Socie´te´ de Pneumologie de
Langue Franc-aise (SPLF).1 European guidelines for nebulisa-
tion were published in English in 20012 and in French in
2004.3,4
The plan to extend the potential use of nebulisation
for bronchodilators, announced as soon as in 2004 and
effective from January 2006, and the realisation that
nebulisation use in France did not correspond precisely to
these national and international guidelines led to set up a
survey in order to deﬁne eventually targeted educational
programmes.Material and methods
Objective and framework of the study
N.U.A.G.E.S was a survey carried out by post, with 12
questions (Table 1) covering the main issues regarding the
use of nebulisation. Repeated testing indicated that it did
not take more than 5–10min to answer the questionnaire.
A total of 3674 questionnaires were analysed, collected
from 2439 general practitioners (GPs), 698 chest physicians
(CPs) and 537 paediatricians (PEs).Analysis of N.U.A.G.E.S
Descriptive analyses of the returned questionnaires
were carried out using multiple correspondence analyses
(MCA).5
Statistical relationships were evaluated using the DEMOD
(DEscription of MODalities) procedure. A p-value of 0.05 or
less was considered as statistically signiﬁcant.Results
Proﬁle of respondents
GPs used nebulisation in few cases and worked with
pharmacists, whereas CPs and PEs, respectively, treated a
signiﬁcant number of patients of two types (adult/elderly
and young) and worked mainly with domiciliary care
services.The reasons for nebulisation
The main reason given by CPs for using nebulisation was ‘‘to
achieve greater efﬁcacy’’ (po0.0001), while GPs mainly
stated that it was ‘‘to obtain local action upstream systemic
resorption’’ (po0.005).
Both CPs and PEs frequently quoted ‘‘administration of
high dosages’’ (po0.0001 and po0.05) with ‘‘no active
involvement of patients’’ (po0.0001), while GPs explained
their choice by ‘‘patient request’’ (po0.005) or ‘‘adminis-
tration at all ages’’ (po0.001).The indications for nebulisation
PEs mainly quoted other indications than those proposed, in
treatments lasting around 1 month (po0.0001).
GPs mainly reported short-term treatments for acute
exacerbation of COPD (po0.0001), tracheitis (po0.05),
bronchitis (po0.0001) and asthma (po0.0001).
CPs primarily reported using nebulisation to treat various
diseases during long-term administration, such as bronch-
iectasis, Pneumocystis carinii pneumonia prevention, cystic
ﬁbrosis, infant bronchiolitis or severe persistent asthma
(po0.0001 in all cases).
Prescriptions for nebulisation
GPs primarily prescribed therapeutic classes without neb-
ulisation approval, i.e. systemic steroids, systemic anti-
biotics and mucolytics in solution (po0.0001 for the three
classes).
In contrast, CPs and PEs declared that they did not
prescribe ‘‘therapeutic classes not approved for nebulisa-
tion’’ (po0.0001).
The totality of the approved therapeutic classes was
prescribed. No main preference emerged for CPs, while PEs
prescribed mainly budesonide, dornase alpha, salbutamol or
tobramycine (po0.0001 for the four drugs).
Nebulising system, training and information
GPs learned about nebulisation from colleagues (po0.0001)
and/or during practical experience (po0.05), whereas CPs
learned about it as part of their specialist training at
medical school (po0.0001).
GPs were interested in all types of information, i.e.
technical (po0.0001), information about drugs (po0.0001),
appropriate nebulising systems (po0.0001) and equipment
supply networks (po0.005), whereas CPs reported no
interest in the proposed information.
GPs reported that they do not write a separate prescrip-
tion for nebulising systems (po0.0001), whereas CPs
and PEs reported prescribing speciﬁc nebulising system
(po0.0001).
Discussion
Most medical teaching programmes in France do not include
nebulisation, and the way nebulisation is taught in specia-
lisation programmes is not standardised. Although a con-
siderable effort has been made to make guidelines widely
available, their impact has not yet been assessed in France.
A local survey of nebulisation performed in 2000 suggested
that French guidelines had had a limited impact.6 The
N.U.A.G.E.S survey was designed to assess the current use of
nebulisation in France, with the aim of deﬁning future post-
graduate teaching programmes.
GPs expressed an interest in any form of training
regarding nebulisation which could be organised in relation-
ship with pharmacists, as they are involved in providing the
nebulising systems. This led to organise early 2006 under the
aegis of SPLF, a large-scale teaching programme on
nebulisation focussed on French pharmacists.
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M. de Monte et al.2564CPs and PEs treat a number of patients, heterogeneous in
terms of diseases, with the hope of an increased efﬁciency,
using drugs approved for administration by nebulisation and
allowing the nebulising system to be provided separately/
independently by home care services. As CPs do not express
any need for speciﬁc training with regard to their use of
nebulisation, it is more difﬁcult to deﬁne the kind of
teaching material to develop for them. Concepts of CD Roms
or brochures are currently under development under the
aegis of the SPLF.
In conclusion, the N.U.A.G.E.S survey, which indi-
cates a very mixed use in France, will be used to
develop targeted educational programmes focussed on
nebulisation.Acknowledgements
This study has been supported by grants from Astra Zeneca
and Glaxo Smith Kline France.References
1. Diot P, Bonﬁls P, Faurisson F, et al. Proposed guidelines for
aerosoltherapy by means of nebulisers in France. Eur Respir Rev
2000;10:206–9.
2. ERS Taskforce. European Respiratory Society Guidelines on the
use of nebulizers. Eur Respir J 2001;18:228–42.
ARTICLE IN PRESS
N.U.A.G.E.S survey 25653. Boe J, Dennis JH, O’Driscoll BR, et al. French implementation of
the ERS guidelines on the use of nebulizers. Rev Mal Respir
2004;21:1033–8.
4. Becquemin MH, Chaumuzeau JP. Editorial on the French
implementation of the ERS guidelines on the use of nebulizers.
Rev Mal Respir 2004;21:889–90.5. Magnant J, de Monte M, Guilmot JL, et al. Relationship between
occupational risk factors and severity markers of systemic
sclerosis. J Rheumatol 2005;32(9):1713–8.
6. Vergnolle F, Rivoire B, Hazouard E, et al. Impact of good clinical
practice for nebulisation in the center region of France. Rev Mal
Respir 2000;17:857–61.
